SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020
-
- Satoshi Kutsuna
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Tadaki Suzuki
- COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
-
- Kayoko Hayakawa
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Shinya Tsuzuki
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Yusuke Asai
- AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Tetsuya Suzuki
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Satoshi Ide
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Keiji Nakamura
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Yuki Moriyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Noriko Kinoshita
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Naoto Hosokawa
- Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
-
- Ryosuke Osawa
- Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
-
- Ryosuke Yamamuro
- Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
-
- Yutaro Akiyama
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Yusuke Miyazato
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Hidetoshi Nomoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Takato Nakamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Masayuki Ota
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Sho Saito
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Masahiro Ishikane
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Shinichiro Morioka
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Kei Yamamoto
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Mugen Ujiie
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Mari Terada
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Fukumi Nakamura-Uchiyama
- Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan
-
- Toshinori Sahara
- Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan
-
- Masahiro Sano
- Department of Infectious Diseases, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Itabashi-ku, Tokyo, Japan
-
- Akifumi Imamura
- Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
-
- Noritaka Sekiya
- Department of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
-
- Kazuaki Fukushima
- Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
-
- Akihiko Kawana
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
-
- Yuji Fujikura
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
-
- Tomoya Sano
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
-
- Ryohei Suematsu
- Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
-
- Naoya Sakamoto
- Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Sumida-ku, Tokyo, Japan
-
- Kaoru Nagata
- Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan
-
- Tomoyuki Kato
- Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan
-
- Harutaka Katano
- COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
-
- Takaji Wakita
- COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
-
- Haruhito Sugiyama
- National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Norihiro Kokudo
- National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
-
- Norio Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
説明
<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) was found to be the causative microorganism of coronavirus disease 2019 (COVID-19), which started to spread in Wuhan, China. This study was to evaluate the effectiveness of questionnaire, symptoms-based screening, and polymerase chain reaction (PCR) screening of returnees from COVID-19-endemic areas on a chartered flight, to examine the proportion of infected persons and the proportion of asymptomatic persons among infected persons who returned from Wuhan.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A retrospective cohort study was done in 7 tertiary medical institutions in Japan. A total of 566 Japanese who returned from Wuhan participated in the study.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Overall, 11 of the 566 passengers had a positive SARS-CoV-2 PCR result for pharyngeal swabs and 6 were asymptomatic. Only fever differed between SARS-CoV-2-positive and -negative individuals (P < .043). Six of the 11 PCR-positive individuals were asymptomatic; 4 remained positive on day 10, and 1 asymptomatic person tested positive up to day 27. Two of the 11 were negative on the first PCR test and positive on the second.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Our results will be important insights on screening returnees from locked-down cities, as well as providing important data on the proportion of asymptomatic individuals infected with SARS-CoV-2. A 13-day observation period and a second round of PCR may be effective to screen patients, including asymptomatic infections.</jats:p> </jats:sec>
収録刊行物
-
- Open Forum Infectious Diseases
-
Open Forum Infectious Diseases 7 (7), 2020-06-20
Oxford University Press (OUP)